Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.40 USD
+0.01 (3.01%)
Updated Jul 15, 2024 03:59 PM ET
After-Market: $0.40 0.00 (-0.17%) 7:44 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RDHL 0.40 +0.01(3.01%)
Will RDHL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RDHL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RDHL
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RDHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RDHL
RedHill Biopharma Terminates License Agreement for Aemcolo®
12 Health Care Stocks Moving In Tuesday's After-Market Session
RedHill Biopharma Announces Board Resignation
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
RedHill Biopharma Secures New Opaganib Patent